IICT Signs Agreement with Sun Pharma Towards Out-licensing of Patents on NCEs
The CSIR-Indian Institute of Chemical Technology here said on Friday that it has signed an agreement withpharma major SunPharma for "out-licensing of patents on a New Chemical Entity for multiple therapeutic indications".
Hyderabad, Aug 16 (PTI) The CSIR-Indian Institute of Chemical Technology here said on Friday that it has signed an agreement withpharma major SunPharma for "out-licensing of patents on a New Chemical Entity for multiple therapeutic indications".
When new compounds are sought to be used as drug candidates, they are named as NCEs, IICT sources said.
As per the agreement, CSIR-IICT will get payments totaling Rs 240 crore, including upfront, development and regulatory and other payments, IICT said in a release.
"Further, the institute will also get payments fromSunPharma through royalties on net sales on commercialization of the products developed using these patents," the release said.
SunPharma will be responsible for development, regulatory filings, manufacturing and commercialization of these potential products, it said.
"This is only a beginning of out-licensing (giving rights to take forward as drugs) NCEs as several patents of CSIR-IICT on NCEs are being negotiated with potential drug development companies.
At this juncture, I am happy to inform that our institute holds India's largest state of the art NCE repository in our campus," S Chandrasekhar, Director of CSIR-IICT, said. PTI
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)